Skip to main content

5 Best Stocks to Buy in March 2025 Based on S&P 500 Low Volume Screen Results


Investing in stocks during a downturn can present an opportunity to acquire high-quality assets at discounted prices. March 2025 brings several intriguing prospects for investors who seek value, dividend income, or potential rebound candidates. The following five stocks, all from the S&P 500 Low Volume 408 Screen, have faced significant price declines year-to-date (YTD). However, their strong fundamentals, attractive dividends, or potential for recovery make them compelling picks.

1. Edison International (EIX)

  • Stock Price: $54.44

  • Sector: Utilities

  • Industry: Electric Utilities

  • Annual Dividend Yield: 6.45%

  • Annual Dividend Rate: $3.31

  • YTD Price Change: -31.81%

Why Buy Edison International?

Edison International, a major player in the electric utilities industry, presents a high-dividend yield stock ideal for income investors. With an impressive 6.45% dividend yield, Edison provides a steady income stream even during market downturns.

Growth and Stability

Utilities are typically resilient, offering stable cash flows regardless of economic conditions. Although Edison International has seen a significant 31.81% YTD decline, the company’s fundamentals remain strong.

The Value Proposition

The recent decline in stock price makes Edison International an attractive bargain for investors looking for defensive stocks with strong dividend payouts. Moreover, as energy demand remains steady and regulations continue to favor renewable energy investments, EIX is well-positioned for a long-term rebound.

Investment Thesis:

  • Strong dividend yield for income investors.

  • Stability from the utilities sector.

  • Potential recovery from oversold conditions.

2. West Pharmaceutical Services Inc. (WST)

  • Stock Price: $232.34

  • Sector: Health Care

  • Industry: Life Sciences Tools & Services

  • Annual Dividend Yield: 0.38%

  • Annual Dividend Rate: $0.84

  • YTD Price Change: -29.07%

Why Buy West Pharmaceutical Services?

West Pharmaceutical Services is a leader in life sciences tools and services, specializing in drug containment and delivery systems. Despite a 29.07% YTD decline, WST remains a fundamentally strong company in the healthcare sector.

Innovation & Market Position

West Pharma is at the forefront of pharmaceutical packaging innovation, benefiting from the rising demand for injectable medications and biologics. Its partnerships with major pharmaceutical firms create a consistent revenue stream.

Growth Potential

While the company’s dividend yield is modest at 0.38%, its potential for capital appreciation is significant. With increasing global demand for advanced drug delivery systems, WST is positioned for long-term growth.

Investment Thesis:

  • High-growth potential in the pharmaceutical packaging industry.

  • Well-positioned for the increasing demand for injectable drugs.

  • Solid fundamentals despite recent price weakness.

3. Celanese Corp (CE)

  • Stock Price: $50.94

  • Sector: Materials

  • Industry: Specialty Chemicals

  • Annual Dividend Yield: 0.24%

  • Annual Dividend Rate: $0.12

  • YTD Price Change: -26.40%

Why Buy Celanese Corp?

Celanese is a global leader in specialty chemicals, supplying various industries, including automotive, industrial, and consumer markets. The stock has dropped 26.40% YTD, presenting an attractive entry point for long-term investors.

Industry Tailwinds

With an increasing demand for engineered materials and sustainable solutions, Celanese's chemical products play a crucial role in industrial manufacturing. Its innovative polymer solutions are expected to gain traction as industries shift towards more advanced materials.

Financial Strength

Although Celanese offers a relatively small dividend yield of 0.24%, its overall financial performance is strong. The company has a track record of solid revenue growth and disciplined capital management.

Investment Thesis:

  • Leading position in specialty chemicals.

  • Growth opportunities in industrial and consumer applications.

  • Attractive valuation following YTD decline.

4. Viatris Inc. (VTRS)

  • Stock Price: $9.23

  • Sector: Health Care

  • Industry: Pharmaceuticals

  • Annual Dividend Yield: 5.04%

  • Annual Dividend Rate: $0.48

  • YTD Price Change: -25.86%

Why Buy Viatris Inc.?

Viatris, a pharmaceutical company, is a global provider of generic and specialty medications. The stock’s 5.04% dividend yield makes it an attractive option for income-focused investors.

Competitive Advantage

Viatris benefits from a diversified product portfolio, with a mix of generic drugs, over-the-counter medications, and complex specialty drugs. Additionally, cost-cutting measures and efficiency initiatives have improved the company’s profitability outlook.

Undervalued Stock

With a stock price of $9.23, Viatris is a deep-value play. The company’s strong cash flow generation and dividend sustainability make it an appealing pick for investors looking for undervalued pharmaceutical stocks.

Investment Thesis:

  • High dividend yield with stable cash flows.

  • Strong presence in generics and specialty pharma.

  • Undervalued price with room for appreciation.

5. Teleflex Inc. (TFX)

  • Stock Price: $132.75

  • Sector: Health Care

  • Industry: Health Care Equipment & Supplies

  • Annual Dividend Yield: 0.98%

  • Annual Dividend Rate: $1.36

  • YTD Price Change: -25.41%

Why Buy Teleflex Inc.?

Teleflex is a leading provider of medical technologies used in surgical, critical care, and cardiovascular procedures. The company’s stock has declined 25.41% YTD, but its long-term growth prospects remain solid.

Market Growth & Stability

Teleflex’s diverse product portfolio spans essential medical equipment, making it a stable business in the healthcare sector. As the aging population increases demand for minimally invasive procedures, TFX is poised for long-term revenue growth.

Strong Fundamentals

Despite recent stock weakness, Teleflex has a history of consistent revenue growth and profitability. Its 0.98% dividend yield offers a moderate income component alongside potential capital appreciation.

Investment Thesis:

  • Market leader in essential healthcare equipment.

  • Increasing demand for minimally invasive medical procedures.

  • Attractive entry point for long-term investors.

Final Thoughts: Which Stock Is Right for You?

Each of these five stocks presents a compelling opportunity based on their sector, dividend yield, and growth potential. Here’s a quick comparison:

  • For income-focused investors: Edison International (EIX) and Viatris (VTRS) stand out with high dividend yields.

  • For growth-oriented investors: West Pharmaceutical Services (WST) and Teleflex (TFX) provide exposure to healthcare innovation.

  • For value investors: Celanese (CE) and Viatris (VTRS) offer discounted prices with strong recovery potential.

As always, investors should conduct their due diligence, considering market conditions and personal financial goals. March 2025 presents a strategic entry point for these five stocks, offering a balance of income, stability, and growth opportunities.

Labels:

Comments

Post a Comment

Popular posts from this blog

Nebius: A 10x AI Growth Story Still Flying Under Wall Street’s Radar

In the world of explosive AI growth stories, few companies combine the stealth, ambition, and scale of Nebius Group N.V. (NASDAQ: NBIS). While Wall Street fawns over the Magnificent Seven and scrambles to understand how OpenAI, Anthropic, and others fit into the commercial AI puzzle, Nebius is quietly building a European AI infrastructure empire—and it’s about to cross the Atlantic. Despite a 20% decline in the stock since February 2025, the company is arguably one of the most compelling under-the-radar growth stories in AI today. If you're a long-term investor searching for the next 10-bagger hiding in plain sight, this one deserves your attention. The Dip Isn't the Story—The Growth Is Let’s begin with the obvious: Nebius stock is down 20% from its recent high. For most momentum chasers, that's a red flag. But the market correction has been broad-based, with the S&P 500 itself in the throes of a selloff sparked by political uncertainty and concerns over rates. Th...
Post a Comment
Read more

Supercharge Your Retirement With Income Machines Paying Fat Dividends

Retirement planning can be a daunting task, but building a portfolio filled with reliable, high-yielding dividend stocks and funds can make it significantly easier. Instead of relying on the traditional 4% rule, where you gradually sell assets to fund your retirement, you can live off dividends indefinitely, preserving your principal while enjoying a steady income stream. By focusing on investments with strong, durable business models, robust balance sheets, and dividend growth that outpaces inflation, retirees can achieve financial security and even benefit from market downturns by reinvesting excess cash flow. In this article, we’ll explore six income-generating investments—three funds and three individual stocks—that can help supercharge your retirement. Fund #1: Schwab U.S. Dividend Equity ETF (SCHD) SCHD is a go-to dividend growth ETF with a well-balanced portfolio of 101 high-quality companies. While its 3.6% dividend yield may be on the lower end for some retirees, its consisten...
Post a Comment
Read more

Higher High, Lower High; AMD Is A Buy

In the ever-volatile world of semiconductors, Advanced Micro Devices (NASDAQ: AMD) (TSX: AMD:CA) is showing all the hallmarks of a classic breakout opportunity—one that savvy investors would be wise not to overlook. Despite a near 50% pullback from its peak, AMD's fundamentals have never looked stronger. And while investor sentiment has temporarily soured, the underlying growth momentum tells a completely different story. We’re witnessing the convergence of a rare market anomaly: robust fundamentals + depressed valuation = opportunity. This is a textbook “higher high, lower high” setup in technical and sentiment terms—when a strong company’s fundamentals climb higher even as its stock price dips lower. Eventually, these two trends reconcile, and when they do, patient investors often see outsized gains. Table of Contents AMD: From Hero to Underdog—Again Unpacking AMD’s Growth Narrative Why the Momentum Is Not Just Sustainable—But Accelerating The Market Is Pricing AMD ...
Post a Comment
Read more